Galmed Pharma (GLMD)
3.88
-0.04 (1.02%)
Upcoming Events
Latest Headlines
Form 6-K/A Galmed Pharmaceuticals For: Jul 22
August 19, 2026 4:05 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Aug 19
August 19, 2026 7:05 AM - SEC Filing
Galmed's Colospan reports feasibility data on tissue assessment tool
August 19, 2026 7:01 AM - StreetInsider
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
August 19, 2026 7:00 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Aug 17
August 17, 2026 9:20 AM - SEC Filing
Galmed's Aramchol shows added cell death in prostate cancer study
August 17, 2026 9:15 AM - StreetInsider
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
August 17, 2026 9:15 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Aug 14
August 14, 2026 4:32 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 31
July 31, 2026 4:06 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 29
July 29, 2026 4:05 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 28
July 28, 2026 7:20 AM - SEC Filing
Galmed develops dissolving film form of Aramchol for Parkinson's disease
July 28, 2026 7:01 AM - StreetInsider
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
July 28, 2026 7:00 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Jul 22
July 22, 2026 4:15 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 16
July 16, 2026 7:43 AM - SEC Filing
Galmed develops heart-targeted nanoparticle formulation of Aramchol
July 16, 2026 7:32 AM - StreetInsider
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
July 16, 2026 7:30 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Jul 08
July 8, 2026 4:15 PM - SEC Filing
Core AI Holdings names Arie Goor as CFO, effective July 1
July 7, 2026 8:20 AM - StreetInsider
Imunon names new interim CFO as predecessor retires
June 30, 2026 4:40 PM - StreetInsider
Form 424B3 Galmed Pharmaceuticals
June 22, 2026 7:05 AM - SEC Filing
Galmed completes Colospan acquisition under restructured terms
June 22, 2026 7:02 AM - StreetInsider
Form 6-K Galmed Pharmaceuticals For: Jun 22
June 22, 2026 7:00 AM - SEC Filing
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
June 22, 2026 7:00 AM - PR NewsWire
Form POS EX Galmed Pharmaceuticals
June 8, 2026 8:36 AM - SEC Filing
Form 424B3 Galmed Pharmaceuticals
June 8, 2026 8:33 AM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jun 08
June 8, 2026 8:26 AM - SEC Filing
Galmed to acquire Colospan for $4.5 million in medical device deal
June 8, 2026 8:11 AM - StreetInsider
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
June 8, 2026 8:11 AM - PR NewsWire
Full Article List
